6 completed, 2 terminated, 1 unknown. 9 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 9 | Completed 6, Terminated 2, Unknown 1 |
| Phase 2 | 2 | Completed 2 |
Follow Glucagon-Like Peptide 1: new trials by email Literature Review of Glucagon-Like Peptide 1 trials Research Report on Glucagon-Like Peptide 1
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus Glucagon Nasal Powder, Glucagon Hydrochloride Solution - Diabetes Mellitus | Phase 3 | Completed | Eli Lilly and Company | 75 | 2018-02-21 | 2019-10-08 |
| A Trial to Confirm the Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in Type 1 Diabetes Subjects Dasiglucagon, GlucaGen, Placebo - Hypoglycemia, Diabetes Mellitus, Type 1 | Phase 3 | Completed | Zealand Pharma | 170 | 2017-12-07 | 2021-06-10 |
| A Trial to Evaluate the Immunogenicity of Dasiglucagon and GlucaGen in Patients With Type 1 Diabetes Mellitus dasiglucagon, GlucaGen - Hypoglycemia, Diabetes Mellitus, Type 1 | Phase 3 | Completed | Zealand Pharma | 112 | 2017-06-28 | 2021-05-04 |
| EQW, DAPA, EQW/DAPA, DAPA/MET ER and PHEN/TPM ER in Obese Women With PolycysticOvary Syndrome (PCOS) Exenatide once weekly (EQW ), Dapagliflozin (DAPA), EQW plus DAPA - Polycystic Ovary Syndrome, Obesity | Phase 3 | Completed | Woman's | 119 | 2016-03-22 | 2021-01-29 |
| Pretreatment of Patients Expecting Bariatric Surgery With the GLP-1 Analogon Liraglutid GLP-1 (Liraglutide), Placebo - Obesity | Phase 3 | Terminated | Universitätsklinikum Hamburg-Eppendorf | 2 | 2011-12-01 | 2022-06-30 |
| Effect of GLP-1 on Glucose Metabolism in CNS Assessed by PET native glp-1 (7-36) - Healthy | Phase 2 / Phase 3 | Completed | University of Aarhus | 10 | 2010-06-01 | 2011-03-22 |
| Modulation of Human Myocardial Metabolism by GLP-1 Dose Response GLP-1 Low Dose, GLP-1 Mid-Range Dose, GLP-1 High Dose - Type 2 Diabetes Mellitus, Healthy | Phase 2 / Phase 3 | Completed | Indiana University | 33 | 2010-05-01 | 2016-02-17 |
| Effect of Sitagliptin on Graft Function Following Islet Transplantation sitagliptin - Islet Transplantation | Phase 3 | Terminated | University of British Columbia | 12 | 2009-07-01 | 2017-10-30 |
| Glucagon Modulation of Ghrelin Secretion Glucagon hydrochloride (GlucaGen®), NaCl 0.9% - Healthy Subjects, Obesity | Phase 3 | Unknown | Charite University, Berlin, Germany | 38 | 2006-06-01 | 2009-06-30 |
Diabetes Mellitus, Type 1 (4) · Obesity (3) · Hypoglycemia (2) · Diabetes Mellitus (1) · Diabetes Mellitus, Type 2 (1) · Insulin Resistance (1) · Polycystic Ovary Syndrome (1)
Zealand Pharma (2) · Charite University, Berlin, Germany (1) · Eli Lilly and Company (1) · Indiana University (1) · University of Aarhus (1) · University of British Columbia (1) · Universitätsklinikum Hamburg-Eppendorf (1) · Woman's (1)
Germany (4) · United States (4) · Canada (3) · Austria (2) · Denmark (1) · Japan (1)
Christina Sylvest, MSc Pharm (2) · Ayman M Arafat, Dr.med. (1) · Birgitte Brock, asso.prof. (1) · David M. Thompson, MD (1) · Drake Bellanger, MD (1) · Jens Aberle, MD (1) · Karen Elkind-Hirsch, PhD (1) · Kieren J Mather, MD (1)
PMID 23966238, PMID 34097062, PMID 35239971, PMID 38444629
R21HL092799 (1)